<博士論文>
オーロラBキナーゼの活性化状態が作用機序の異なる微小管結合性抗癌剤の効果に及ぼす影響

作成者
論文調査委員
本文言語
学位授与年度
学位授与大学
学位
学位種別
出版タイプ
アクセス権
JaLC DOI
関連DOI
概要 Tubulin-binding agents (TBAs) are designed to target microtubule (MT) dynamics, resulting in compromised mitotic spindles and an unsatisfied spindle assembly checkpoint. The activity of Aurora B kinas...e is indispensable for TBA-induced mitotic arrest, and its inhibition causes mitotic slippage and postmitotic endoreduplication. However, the precise phenomenon underlying mitotic slippage, which is caused by treatment with both Aurora B inhibitors and TBAs, and the cell fate after postmitotic slippage are not completely understood. Here, we found that HeLa and breast cancer cells treated with the different types of TBAs, such as paclitaxel and eribulin (MT-stabilizing and MT-destabilizing agents, respectively), exhibited distinct behaviors of mitotic slippage on inhibition of Aurora B. In such conditions, the cell fates after postmitotic slippage vastly differed with respect to cell morphology, cell proliferation, and cytotoxicity in short-term culture; that is, the effects of inhibition of Aurora B were beneficial for cytotoxicity enhancement in eribulin treatment but not in paclitaxel. However, in long-term culture, the cells that survived after mitotic slippage underwent endoreduplication and became giant cells in both cases, resulting in cellular senescence. We propose that MT-destabilizing agents may be more appropriate than MT-stabilizing agents for treating cancer cells with a weakened Aurora B kinase activity.続きを見る

本文ファイル

pdf med3132 pdf 3.54 MB 293 本文
pdf med3132_abstract pdf 157 KB 277 要旨
pdf med3132_review pdf 167 KB 174 審査結果要旨

詳細

レコードID
査読有無
権利関係
関連PubMed ID
報告番号
学位記番号
授与日(学位/助成/特許)
受理日
部局
登録日 2018.05.30
更新日 2023.07.31

この資料を見た人はこんな資料も見ています